文章：

非小细胞肺癌伴表皮生长因子受体（EGFR）常见突变：新策略探讨

Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor (EGFR) Common Mutations: New Strategies

原文发布日期：30 April 2025

DOI: 10.3390/cancers17091515

类型: Article

开放获取: 是

英文摘要：

Epidermal growth factor receptor (EGFR) mutations are described in 10–15% of Caucasian patients and in 50% of Asian patients with non-squamous non-small cell lung cancer (NSCLC). The introduction of tyrosine kinase inhibitors (TKIs) has revolutionized the therapeutic scenario and has changed the natural history of the disease. Despite the results obtained with osimertinib, a third-generation TKI, most patients experience disease progression. The search for new therapeutic strategies both to enhance first-line treatment and to ensure adequate second-line therapies represents an unmet medical need, towards which all efforts are being concentrated. In this review, we describe the main strategies identified to improve the prognosis of patients with EGFR-mutated NSCLC.

摘要翻译： 

表皮生长因子受体（EGFR）突变在非鳞状非小细胞肺癌（NSCLC）患者中的发生率存在显著地域差异：白种人群约为10-15%，而亚洲人群可达50%。酪氨酸激酶抑制剂（TKIs）的问世彻底改变了该疾病的治疗格局，并扭转了其自然病程。尽管第三代TKI药物奥希替尼已取得显著疗效，但多数患者仍面临疾病进展的挑战。当前临床亟需探索既能增强一线治疗效果、又能提供有效二线治疗的新策略，这已成为医学界集中攻关的重点方向。本综述系统阐述了目前为改善EGFR突变NSCLC患者预后所确立的主要治疗策略。

原文链接：

Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor (EGFR) Common Mutations: New Strategies